We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTyra Biosciences Inc

Tyra Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
20.34 USD -0.63 ( 3.00%)
Last update at 2026-11-12T15:47:00Z
VOLUME
133977
Market Cap
1748.46M

Momentum Score

…

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
19.66
Low
21.43
High
52 Week Price Range
12.27
Low
40.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Based on available public information, Tyra Biosciences is a clinical-stage biotechnology company focused on developing precision oncology therapies using biomarker-driven approaches. Long-term growth may be driven by clinical trial progress for its pipeline candidates, potential regulatory approvals, strategic collaborations, and successful patient selection, which could support future revenue and licensing opportunities; investors may find the company attractive for its focused development strategy and targeted indications.
The principal investment risks include typical early-stage biotech exposures such as clinical and regulatory failure, high cash burn and dilution if additional financing is required, competitive pressures in oncology, and execution dependence on partnerships and trial milestones.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
20.97
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-45.31%
Net Debt
-71.58M
ROCE
-45.35%
Diluted EPS TTM
-2.42

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -119.95M -86.48M -69.13M -55.33M -26.29M
Net income -119.95M -86.48M -69.13M -51.72M -26.14M
Selling general administrative 29.83M 24.10M 17.43M 15.92M 5.65M
Selling and marketing expenses - - 17.41M - -
Gross profit -0.55M -0.52M -0.35M - -
Reconciled depreciation 0.55M 0.52M 0.35M 0.30M 0.14M
Ebit -119.95M -86.48M -69.13M -59.22M -26.43M
Ebitda -119.40M -85.96M -68.78M -58.93M -26.29M
Depreciation and amortization 0.55M 0.52M 0.36M 0.30M 0.14M
Non operating income net other - - - 3.60M -0.01M
Operating income -132.76M -104.18M -79.94M -58.93M -26.29M
Other operating expenses 132.76M 104.18M 79.94M 58.93M 26.29M
Interest expense - - - 0.30M 0.14M
Interest income 12.81M 17.70M 10.85M 3.65M 0.01M
Net interest income 12.81M 17.70M 10.85M 3.65M 0.01M
Income tax expense - - - -3.60M -0.15M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 132.76M 104.18M 79.94M 58.93M 26.29M
Cost of revenue 0.55M 0.52M 0.35M - -
Total other income expense net 12.81M 17.70M 10.81M 3.60M -0.01M
Net income from continuing ops -119.95M -86.48M -69.13M -55.33M -26.29M
Net income applicable to common shares - - - -55.33M -26.29M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 282.61M 363.56M 225.86M 266.18M 306.70M
Other current assets 9.45M 4.02M 7.50M 6.08M 1.88M
Total liab 23.43M 20.41M 21.59M 8.35M 4.96M
Total stockholder equity 259.18M 343.15M 204.26M -95.70M 301.74M
Other current liab 16.44M 13.59M 10.39M 4.42M 2.81M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -371.26M -251.31M -164.83M -95.70M -40.37M
Other liab - - - 0.17M 0.37M
Other assets - - - 5.35M 0.56M
Cash 77.39M 91.97M 58.01M 251.21M 302.18M
Total current liabilities 18.09M 14.59M 15.33M 5.70M 3.62M
Net debt -71.58M -85.74M -51.51M -248.59M -301.00M
Short term debt 0.47M 0.41M 0.28M 0.14M 0.20M
Short long term debt total 5.81M 6.22M 6.50M 2.62M 1.18M
Other stockholder equity 630.04M 593.69M 368.71M -0.00M 342.10M
Property plant equipment - - - 1.08M 1.03M
Total current assets 265.45M 347.46M 211.67M 257.29M 304.06M
Net tangible assets - - - 257.83M 301.74M
Short term investments 178.62M 249.47M 145.46M - -
Net receivables - 2.00M 0.70M - -
Accounts payable 1.18M 0.59M 4.66M 1.15M 0.60M
Accumulated other comprehensive income 0.39M 0.77M 0.38M - -306.70M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -95.70M -40.37M
Non currrent assets other 10.27M 8.38M 5.03M 5.35M 0.56M
Non current assets total 17.16M 16.09M 14.19M 8.89M 2.64M
Capital lease obligations 5.81M 6.22M 6.50M 2.62M 1.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 72.60M -98.40M -144.60M -0.56M -0.65M
Change to liabilities - - - 2.36M 1.49M
Total cashflows from investing activities 72.46M -98.40M -144.60M -0.56M -0.65M
Net borrowings - - - - -0.03M
Total cash from financing activities 8.10M 202.14M 1.54M 0.63M 311.35M
Change to operating activities - - - -8.20M -1.97M
Net income -119.95M -86.48M -69.13M -55.33M -26.29M
Change in cash -14.58M 33.96M -193.21M -50.21M 286.96M
Begin period cash flow 92.97M 59.01M 251.21M 302.43M 15.47M
End period cash flow 78.39M 92.97M 58.01M 252.21M 302.43M
Total cash from operating activities -95.14M -69.77M -50.14M -50.28M -23.75M
Issuance of capital stock 0.00M 200.00M 0.00M 0.00M 310.84M
Depreciation 0.55M 0.52M 0.36M 0.30M 0.14M
Other cashflows from investing activities - - - - 0.02M
Sale purchase of stock 0.00M -0.42M 0.00M - 311.38M
Other cashflows from financing activities 8.10M 2.56M 1.54M -0.56M 130.14M
Change to netincome - - - 10.59M 2.89M
Capital expenditures 0.14M 0.66M 0.77M 0.56M 0.66M
Cash flows other operating - - - -8.20M -1.97M
Cash and cash equivalents changes - - - -50.21M 286.96M
Change in working capital -1.63M -0.73M 6.36M -5.85M -0.48M
Stock based compensation 28.01M 22.80M 13.53M 10.59M 2.89M
Other non cash items -2.12M -5.88M -1.25M 0.00M 0.00M
Free cash flow -95.28M -70.44M -50.91M -50.84M -24.41M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
TYRA
Tyra Biosciences Inc		 -0.63
3.00%		 20.34 - - - 4.94 -6.95
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Tyra Biosciences Inc

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

2656 State Street, Carlsbad, CA, United States, 92008

619 728 4760

https://tyra.bio

87

Name Title Year Born
Dr. Todd Harris Ph.D. Pres, CEO, Sec., Treasurer & Director 1979
Dr. Ronald V. Swanson Ph.D. Chief Scientific Officer 1963
Dr. Hiroomi Tada M.D., Ph.D. Chief Medical Officer 1964
Mr. Daniel Bensen Co-Founder & COO 1975
Lynn Scherm Fin. Director NA
Ms. Esther van den Boom CPA, CPA Chief Financial Officer 1980
Dr. Robert L. Hudkins Ph.D. Chief Technology Officer 1955
Mr. Ali D. Fawaz J.D. Gen. Counsel & Sec. NA
Dr. Piyush R. Patel Ph.D. Chief Devel. Officer 1965
Amy Conrad Investor Contact NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…